Gilead Sciences (GILD) 8-K Gilead Sciences Receives Subpoena from U.s. Department of Justice

	CONTACTS:	Susan Hubbard, Investors (650) 522-5715
		Amy Flood, Media (650) 522-5643
For Immediate Release

GILEAD SCIENCES RECEIVES SUBPOENA FROM U.S. DEPARTMENT OF JUSTICE

Foster City, CA, December 7, 2006– Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has received a subpoena from the United States Attorney’s Office in San Francisco requesting documents regarding its marketing and medical education programs for Truvada^® (emtricitabine and tenofovir disoproxil fumarate), Viread^® (tenofovir disoproxil fumarate) and Emtriva^® (emtricitabine). Gilead intends to comply with the U.S. Attorney’s subpoena and to cooperate in any related government investigation.

About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

# # #

For more information on Gilead Sciences, please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).